The hyperpolymorphic HLA genes play important roles in disease and transplantation and act as genetic markers of migration and evolution. A panel of 107 B-lymphoblastoid cell lines (B-LCLs) was established in 1987 at the 10th International Histocompatibility Workshop as a resource for the immunogenetics community. These B-LCLs are well characterised and represent diverse ethnicities and HLA haplotypes. Here we have applied Pacific Biosciences' Single Molecule Real-Time (SMRT) DNA sequencing to HLA type 126 B-LCL, including the 107 International HLA and Immunogenetics Workshop (IHIW) cells, to ultra-high resolution. Amplicon sequencing of full-length HLA class I genes (HLA-A, -B and -C) and partial length HLA class II genes (HLA-DRB1, -DQB1 and -DPB1) was performed. We typed a total of 931 HLA alleles, 895 (96%) of which were consistent with the typing in the IPD-IMGT/HLA Database (Release 3.27.0, January 20, 2017), with 595 (64%) typed at a higher resolution. Discrepant types, including novel alleles (n = 10) and changes in zygosity (n = 13), as well as previously unreported types (n = 34) were observed. In addition, patterns of linkage disequilibrium were distinguished by four-field resolution typing of HLA-B and HLA-C. By improving and standardising the HLA typing of these B-LCLs, we have ensured their continued usefulness as a resource for the immunogenetics community in the age of next generation DNA sequencing.
| INTRODUCTION
The HLA genes, located within the major histocompatibility complex (MHC), are some of the most polymorphic genes in the human genome. [1] [2] [3] HLA molecules present self and antigenic peptides to the immune system and thus are the primary genetic barrier to allogeneic transplantation of solid organs and haematopoietic stem cells. 4 They also contribute to disease susceptibility 5, 6 and are useful genetic markers of human evolution. [7] [8] [9] The importance of HLA in the field of immunogenetics has been recognised for many decades. In 1987, the 10th International Histocompatibility Workshop established a panel of 107 B-lymphoblastoid cell lines (B-LCLs) 10, 11 as a reference for many HLA alleles and haplotypes. These cell lines represent diverse ethnicities with many being homozygous and/or consanguineous, and they remain some of the best characterised in the immunogenetics field to date.
Over the years, HLA typing has developed from serology, to molecular methods using oligonucleotide probes and polymerase chain reaction (PCR), to sequence-based typing, 12 which can now be performed by next generation sequencing platforms. 13 But despite technological advances, challenges of gene coverage and phasing polymorphisms remain, often resulting in ambiguous HLA typing results. To date, most known HLA alleles are distinguished by differences in their peptide-binding domain, encoded by exons 2 and 3 of HLA class I alleles and in part by exon 2 of the genes encoding the β-chain of HLA class II molecules. The DNA sequence of these regions is thus a minimum requirement for submission of a novel HLA allele to the IPD-IMGT/HLA Database. 14 Other regions of both coding and non-coding variation outside the peptide-binding domain, in other exons, introns and untranslated regions (UTRs), have been largely overlooked until recently due to technology limitations. Polymorphism in these regions could have profound structural, functional and regulatory effects on the HLA molecules, potentially with widespread clinical implications, particularly in the field of transplantation. [15] [16] [17] [18] [19] Thus high resolution, unambiguous HLA typing is of great value to histocompatibility laboratories, as well as clinical and anthropological researchers alike. Pacific Biosciences' Single Molecule Real-Time (SMRT) DNA sequencing has the potential to overcome the aforementioned technical challenges and deliver truly allelic level HLA typing. 20 The long read lengths generated allow sequencing of full-length HLA class I genes, 21 with the potential to extend this to full-length HLA class II in the near future. 22 Alleles are sequenced in isolation, resolving phase and reducing or removing ambiguity. Anthony Nolan's Histocompatibility Laboratory now routinely uses SMRT sequencing for HLA typing. Our current strategy involves sequencing of full-length HLA class I genes and partial regions of HLA class II genes, 23 targeting at least the exons encoding the extracellular domains of the mature HLA proteins. We have applied this strategy to HLA type 126 B-LCLs, including the 107 cells lines from the 1987 10th International HLA and Immunogenetics Workshop (IHIW) reference panel, with the aim of improving and standardising the resolution of their HLA typing in the IPD-IMGT/HLA Database for the age of next generation DNA sequencing. In doing so we identified numerous discrepancies and novel intronic polymorphisms, extended several alleles to full genomic sequences, and confirmed the existence of some alleles identified by other researchers.
| MATERIAL AND METHODS
A total of 126 B-LCLs were selected for HLA typing, including the 107 cell lines of the IHW reference panel.
Within the reference panel there are three pairs of duplicated cell lines: OLGA (IHW9071) and OLL (IHW9100), SPL (IHW9101) and SPACH (IHW9072), and LBF (IHW9096) and LBUF (IHW9048). We only sequenced one cell of each of these for our study (OLL, SPL and LBF, respectively), so the number of unique cell lines from the panel is 104. The additional 22 cell lines have been extensively characterised in our laboratory and represent some less common alleles not observed in the reference panel.
Briefly, PCR amplifications of HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 were performed using DNA barcoded primers and protocols designed in-house and described previously. 21, 23 The regions amplified for each of the HLA genes are shown in Table 1 . Amplifications of HLA class I and DRB1 were performed with TaKaRa LA DNA polymerase (Takara Bio Europe SAS, Saint-Germain-en-Laye, France). DPB1 and DQB1 amplifications were performed with PrimeSTAR GXL DNA polymerase (Takara Bio Europe SAS). Barcoded amplicons were quantified for concentration and size on a Fragment Analyser capillary electrophoresis system in combination with PROSize data analysis software (Advanced Analytical Technologies, Ankeny, Iowa) before being pooled to equinanogram concentrations for each locus. Locus pools were purified and concentrated to remove residual primers, primer dimers and free nucleotides using AMPure beads (Pacific Biosciences, Menlo Park, California) before re-quantifying on a Fragment Analyser. Size and concentration were used to generate HLA class I and class II equimolar pools containing HLA-A, -B, -C and -DRB1, -DQB1, -DPB1 amplicons, respectively. The SMRTbell library preparation was performed according to manufacturer's protocol (Pacific Biosciences, Menlo Park, California) for libraries greater than 3 kb in size using SMRTbell Template Prep Kit 1.0. Briefly, equimolar pools were subjected to DNA damage repair and end repair before SMRTbell adaptors were ligated onto the ends of the PCR amplicons. The ligation stage was followed by exonuclease treatment and 3 subsequent AMPure purifications. The resulting SMRTbell libraries were quantified on a Fragment Analyser to determine the library size and concentration for the Binding Calculator (Pacific Biosciences). The Binding Calculator protocols for each library were followed Typing results generated by SMRT sequencing were accepted if the read depth was approximately 50 reads or higher and the quality value (QV) was approximately 42.00, the maximum set by our analysis software. The QV is a Phred-like quality score generated by Pacific Biosciences' SMRTAnalysis software reflecting the total probability that a basecall is an insertion or substitution or is preceded by a deletion. Typing results that were consistent with the IPD-IMGT/HLA Database for each locus and cell line were accepted. Where HLA typing for particular loci was previously unreported for a cell line entry in the IPD-IMGT/ HLA Database, our SMRT sequencing allele type was accepted. Any typing that suggested the presence of novel polymorphisms or showed discrepancies to the typing in the IPD-IMGT/HLA Database was repeated from the PCR stage, as per our previous validation of this technique that included Sanger sequencing. 21, 25, 26 Repeat sequencing was also performed for HLA class I alleles that were not in the IPD-IMGT/HLA Database as full-length genomic sequences. Our current HLA class II strategy does not cover the entire length of the gene, so for consistency here we report only three-field resolution (ie, coding sequence) typing for HLA class II alleles. To compare the typings generated by SMRT sequencing to those in the IPD-IMGT/HLA Database, criteria were established for consistency and resolution of typing as follows. SMRT sequencing typing was deemed as higher resolution if the typing had a greater number of fields than the previous typing, reduced or resolved an ambiguous string, or if the previous type was unreported. SMRT sequencing typing was deemed as consistent with previous typing if the typed allele was the same as the previous typing, regardless of resolution. SMRT sequencing typing was deemed as discrepant if the typed allele was different to the original allele or if there was a change in zygosity.
| RESULTS
Read numbers and QV varied between allele typings due to the representation of those alleles in the library from PCR efficiency, equinanogram and equimolar pooling stages. Productivity of the sequencing and level of multiplexing also contribute to read numbers and quality. High productivity in a SMRT sequencing reaction is indicated by a high P1 value. Generally, we accepted sequencing runs as successful if the P1 was ≥30%, meaning that at least 30% of zero-mode waveguides (ZMWs) contained a single SMRTbell with a single functional polymerase molecule. However, we assess the quality of a particular sequence on an individual basis based on read numbers and the QV. Because the typing results generated here were performed over multiple sequencing runs, the collation of all sequence quality-related data would become prohibitively time-consuming. The sequence quality data from representative HLA class I and class II sequencing runs, each with 35 samples, is summarised here ( Table 2) . Across all six loci in these two sequencing runs, the mean number of reads per allele was 305 (min. 48, max. 500) and the mean QV was 42.00 (min. 41.81, max. 42.00).
Full HLA typing results can be found in Table 3 . In summary, across the 126 cell lines, 931 SMRT sequencing allele types were generated representing 208 unique alleles, 895 (96%) of which were consistent with the typing in the IPD-IMGT/HLA Database, with 595 (64%) typed at a higher resolution. We observed 36 instances of discrepant types that are detailed in Table 4 . These included 10 novel alleles and 13 changes in zygosity, all but one of which were a change from homozygous to heterozygous. Four changes in zygosity were due to an additional allele with a different coding sequence, while eight changes in zygosity were a result of additional intronic variants, four of which were novel alleles. One example of a synonymous coding variant (A*24:02:43) in addition to the common (A*24:02:01:01) allele was observed in cell line LKT3. Only one cell line (E4181324) was previously heterozygous (C*12:02:01, C*12:02:02) and is now known to be homozygous for a C*12:02:02. All of the novel intronic variants of HLA class I alleles were a result of single nucleotide polymorphisms (SNPs) relative to existing alleles, with the exception of the novel B*49:01:01:02 in BM15 that differs from the B*49:01:01:01 at two adjacent nucleotide positions, most likely as a result of recombination event. Additionally, 34 allele types previously unreported for some cell lines were sequenced (Table 3) . Nine discrepancies in HLA class II alleles were a result of limited exon coverage during original typing (Table 4) , which has been limited to exon 2 for these loci in the past. This affected two cell lines (31227ABO and FH05) originally typed as a DRB1*14:01 and now known to contain the more common DRB1*14:54:01 where the alleles differ by a SNP in exon 3. Four cell lines (PMG075, LWAGS, GEE018 and BM15) originally typed as a DPB1*03:01 are now known to have a DPB1*104:01, where the alleles differ by a SNP in exon 4. One cell line (AMAI) was previously typed as a DPB1*04:02 but we identified it as a DPB1*105:01, where the alleles differ by a SNP in exon 3. Cell line BM15 was typed as a DQB1*03:01 previously but was found to be a DQB1*03:19, where the alleles differ by a SNP in exon 3. Finally, cell line FH13 was originally typed as a DPB1*02:01:02 with a DPB1*13:01. We identified the DPB1*02:01:02 but typed a DPB1*133:01 instead of the DPB1*13:01. Interestingly, DPB1*13:01 and DPB1*133:01 are identical over exon 2 while DPB1*02:01:02 and DPB1*133:01 are identical over exon 3. The likely explanation for this discrepant typing is that the DPB1*13:01 of FH13 was submitted in 2004 based on exon 2 sequence alone, before the naming of the DPB1*133:01 allele in 2011. The sequences suggest DPB1*133:01 arose from a recombination between a DPB1*02:01:02 and a DPB1*13:01, as there are multiple polymorphisms distinguishing their exons. This result highlights the advantages of long read lengths generated in isolation by SMRT sequencing to resolve potential ambiguities particularly from recombinants, as a Sanger sequencing of exons 2 and 3 separately would not allow disambiguation of the potential allele combinations.
We submitted 28 full-length genomic sequences of HLA class I alleles to the IPD-IMGT/HLA Database, including 10 novel alleles and 6 extensions of existing alleles. Additionally, three corrections and nine confirmations of existing genomic sequences were identified (Table 4) . Confirmations of allele sequences in the IPD-IMGT/HLA Database, particularly from different source samples and sequencing platforms, is vital for determining which alleles are real or could have been a result of errors. Many of the 107 cell lines in the IHW panel were the source of reference sequences for particular alleles, while others have been typed by various DNA-based or serological methods.
Some discrepancies we observed cannot be explained by limited exon coverage and more likely suggest technology limitations at the time of submission or erroneous sequences or submissions to the IPD-IMGT/HLA Database. It is worth noting that cell line data for some loci in the IPD-IMGT/HLA Database is based on typing not sequencing, which may contribute to the discrepancies observed here. For example, cell line HID was thought to be homozygous for an A*02:01 allele but SMRT sequencing shows that it has both an A*02:01:01:01 and an A*02:06:01:01. Despite these alleles differing in exon 2 by two SNPs, the original typing method used may not have been able to differentiate an A*02:01 from A*02:06 even though both alleles were known in 1992 when the cell line was first submitted to the IPD-IMGT/HLA Database. Some discrepancies may be the result of human error, such as the original typing of CB with a DPB1*19:01 as in the similarly spelled cell line CB6B, whereas we have typed CB as having a DPB1*04:01:01. Some of the discrepancies we observed between our SMRT sequencing and the IPD-IMGT/HLA Database suggest that some original sequences were erroneous and may not exist. Consistent with the findings of Voorter et al 27 cell line AZL, the reference cell for A*02:17:01, was typed here as an A*02:17:02. We corrected this typing for LZL and in this study confirmed the A*02:17:02 in its HLA identical sibling AZL ( Table 4) . As no other examples of this allele sequence in full have been submitted, it is likely that the A*02:17:01 does not exist and should be removed from the IPD-IMGT/HLA Database. Another example is that of DRB1*08:02:02 from OLL. We sequenced OLL as DRB1*08:02:01 (Table 4) , as in SPL, another cell line potentially sharing the same haplotype.
Numerous patterns of linkage disequilibrium (LD) were observed between HLA-B and -C (Table 5) . Of 51 unique HLA-B and 35 unique HLA-C alleles, we observed 68 different combinations of alleles. This is consistent with current observations that HLA-B is more polymorphic than HLA-C, reflected by the number of HLA-B and -C alleles in the IPD-IMGT/HLA Database at 4647 and 3832, respectively. By direct counting alone, half of these associations (n = 34) were observed only in a single cell line, while the remaining 34 were represented between 2 and 11 cell lines. Where we were able to type to four-field resolution, we observed some associations that were distinguishable by the fourth field. For example, B*18:01:01:01 alleles were observed in LD with C*05:01:01:01 in six cell lines (VEN, DUCAF, EJ32B, JVM, L0081785 and QBL), while B*18:01:01:02 alleles were observed in LD with C*07:01:01:01 and C*12: 03:01:01 in two (31227ABO and BM16) and one cell lines (DO208915), respectively. All of these cell lines are Caucasoid although there is potentially a division between northern and southern Europeans for these haplotypes. A clearer example of the effect of ethnicity was observed with B*40:06:01:01 in LD with C*08:01:01 in two Japanese cell lines (HID and KT14), while B*40:06:01:01 was in LD with a HLA-C*12:02:02:01 in a Gypsy, Caucasoid cell line from Spain (G085). Patterns of LD in HLA 8 and across the human genome 28 are known to be ethnicity dependent. 
| DISCUSSION
We have effectively demonstrated the ability of Pacific Biosciences' SMRT DNA sequencing to generate full-gene, high resolution, unambiguous typing of HLA class I, and partial gene typing of HLA class II. We applied this technology to sequence HLA genes from 126 B-LCLs, many of which had been previously well-characterised for HLA as part of the 10th IHW panel. The vast majority of our typing results were consistent with those in the IPD-IMGT/HLA Database and we were able to increase the resolution of typing for two-thirds of the alleles. Many HLA alleles, particularly those that are less common, are only represented in the IPD-IMGT/HLA Database to three or even two-field resolution because no intronic or synonymous variants of them have been discovered, respectively. Here, despite not necessarily increasing the number of fields of resolution for some allele types, we have extended them to full-length genomic sequences (HLA class I) or covered at least the regions encoding the extracellular domains of the mature HLA proteins (HLA class II). The advantages of SMRT sequencing for HLA typing are the long read lengths generated in isolation, which allow phasing of polymorphisms across several kilobases of DNA sequence. Additionally, the nature of errors generated by SMRT sequencing is generally believed to be random and therefore sequencing of repeat regions is performed accurately with sufficient sequencing depth, 29, 30 although some homopolymer repeat regions may remain problematic. 31 By their nature, repeat DNA sequences are located in variable regions of the genome. This coupled with the limitations of Sanger, 454 pyrosequencing and Illumina sequencing by synthesis to correctly call all bases in long repeat regions has made them particularly notorious. Recent combination uses of SMRT and Illumina sequencing perform better at sequencing through these regions than either platform alone. 32, 33 We did observe some discrepancies to allele ref-
erence sequences in homopolymer regions. These occurred at particular positions in certain alleles and could be a result of sequencing errors, real polymorphism or erroneous reference sequences as a result of the limitations of historical technology. Increased sequencing depth resolved these discrepancies in some cases. When these discrepancies consistently appeared the quality of individual sub-reads was investigated. In all cases, a drop in quality around this region indicated a sequencing error and these results were deemed as such, Future optimisation of SMRTAnalysis by Pacific Biosciences and of our bioinformatics pipeline {AT}Toolset should determine the nature of these discrepancies with more confidence in future.
There are several next generation sequencing-based strategies being applied to HLA typing. [34] [35] [36] [37] [38] Recently, a capture oligonucleotide probe and Illumina sequencingbased study carried out KIR and HLA class I typing on 97 IHW cell lines. 39 Of the 126 cell lines we typed with SMRT sequencing, 80 were also typed in the probeIllumina study, but the results were not totally consistent between the two methods. Generally both studies agreed where previous typing had been limited to particular exons. However, the probe-Illumina study failed to detect changes in zygosity and intronic polymorphisms in some cell lines that we observed with SMRT sequencing. It is possible that probe capture or Illumina sequence coverage were not sufficient over intronic regions to be able to differentiate these polymorphisms. There could also potentially be issues with resolving phase in heterozygous samples. These pitfalls were avoided with our SMRT sequencing approach where full-gene amplicons were sequenced, providing balanced coverage across the molecule. The typing of HLA class I alleles to four-field resolution allowed patterns of LD to be examined in more detail. The LD between HLA-B and -C and between HLA-DRB1 and -DQB1 results in common associations of these pairs of alleles, which can be indicative of particular ethnicities and haplotypes. The allelic level typing data generated here showed that different HLA-C alleles associate with different intronic variants of the same HLA-B allele. This was observed across eight European Caucasoid cell lines with different haplotypes. It is likely that a similar pattern will emerge between HLA-DRB1 and -DQB1 as more full- will be needed to assess the frequencies of these associations and haplotypes in different ethnic populations as well as their clinical relevance. It could be argued that the majority of the world's population are admixed to some extent. But despite the associations between ethnicity and different HLA alleles, 8, 9 the former is often vague and self-determined. For example, in a highly admixed population (Brazil), HLA typing was shown to be a better indicator of ethnicity than self-determined skin colour. 41 One important clinical application of high-resolution HLA typing is that of matching donors and patients for haematopoietic stem cell transplantation (HSCT). Currently, matching patient and donor ethnicity for HSCT is not a recommendation of the British Society for Histocompatibility and Immunogenetics. 42 However, matching for haplotypes, which are linked to ethnicities, 43 rather than alleles alone could be used to improve clinical outcome after HSCT. 16, 44 These data reinforce the argument for full-length gene sequencing as a method of HLA typing, where intronic polymorphisms can be used to infer haplotypes. This would reduce the need for time-consuming family studies, which are not always possible, and decrease the time to transplant, which is beneficial to the patient.
45-47
While we perform full-gene sequencing of HLA class I, a current limitation of our SMRT sequencing strategy is that HLA class II alleles with known polymorphisms outside the regions we sequenced were unable to be differentiated here, resulting in albeit short but ambiguous strings for some alleles. However, this strategy is much improved in terms of exon coverage compared to even recent strategies that looked at only exon 2 and exon 3, 37 and would have many more ambiguous types in this dataset. We are currently developing a full-length HLA class II typing strategy 22 which will allow us to deliver truly allelic level HLA typing across the six classical HLA loci. In future, this will allow better matching of patients and donors for improved HSCT outcome as well as provide detailed information on HLA haplotype evolution. The work presented here has further demonstrated the efficacy of SMRT sequencing to provide the highest resolution, unambiguous HLA typing data when full genes are sequenced. This has improved and standardised the HLA typing data for 126 cell lines, including those of one of the most well-characterised reference panels. In doing so, we have generated new full-length genomic sequences for some alleles, including those where we have identified novel intronic polymorphisms. We have also rectified previously incorrect HLA types and identified patterns of LD distinguishable by only the highest resolution typing. This knowledge ensures the continued usefulness of the reference cell line panel as a resource to the immunogenetics community in the age of next generation DNA sequencing.
